search
Back to results

Biocellular-Cellular Regenerative Treatment Scaring Alopecia and Alopecia Areata (SAAA)

Primary Purpose

Alopecia Areata, Scarring Alopecia

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
tSVF by lipoaspiration
PRP Concentration
Emulsification tSVF
cSVF isolation and concentration
cSVF in Normal Saline IV
Sponsored by
Regeneris Medical
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Alopecia Areata focused on measuring Stem Cells,PRP, tSVF,cSVF,Alopecia Areata,Scarring Alopecia

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Males with a biopsy proven diagnosis of a Scaring alopecia (SA) or Alopecia Areata (AA)
  2. Females with a biopsy proven diagnosis of Scaring alopecia (SA) or Alopecia Areata (AA)
  3. Demonstrated ability to legally provide written informed consent and comply with the study requirements
  4. For women of childbearing potential with screening negative pregnancy test and subject agrees to avoid pregnancy with two forms of contraception for the duration of study
  5. Subject is willing to maintain existing and consistent hair length and color.
  6. Ability to complete study procedures, patient surveys, and photodocumentation.
  7. Subject is ≥ 18 years of age.
  8. Five (5) year cancer free period without treatment and no evidence of recurrence

    -

Exclusion Criteria:

  1. Subjects who have used oral spironolactone, finasteride, dutasteride, minoxidil, or any oral or topical medication including over the counter and herbal medications for the treatment of hair loss within 12 months of study screening.
  2. Simultaneous treatment with an investigational product or procedure within 30 days, or planned future participation in another clinical study
  3. Subject has previously failed or has been deemed non-responsive to a previous experimental hair loss treatment.
  4. Subject must have no recent PRP, biocellular treatments, micro needling, cold laser therapies, or any other scalp or hair loss treatment.
  5. Subject with previously diagnosed or suspected unspecified dermatologic condition, or disorders that will make hair growth difficult (such as systemic burns, etc.).
  6. History of or active diagnosis of systemic autoimmune disease or organ transplantation or immunosuppressive medication(s).
  7. Receiving active cancer treatment or have present or previous malignancies except a history of squamous or basal skin cell carcinoma with excision for cure.
  8. Active systemic infection at the time of enrollment. If acquired afterwards, exclusion based on clinical judgment of investigator.
  9. Use of chronic antibiotics and/or systemic corticosteroids.
  10. Use of systemic agents that increase bleeding or clotting, or disorders associated with these effects, including patients receiving GIIB/IIIa inhibitors in the 2 weeks prior to the study procedure through to 1 week after the study procedure.
  11. Clinically significant or current medical or psychiatric illness.
  12. Prior surgery in the treatment area.
  13. Any disease or condition (medical or surgical) that, in the opinion of the investigator, might compromise dermatologic, hematologic, cardiovascular, pulmonary, renal, gastrointestinal, hepatic, or central nervous system function; or any condition that would place the subject at increased risk of increased morbidity or mortality.
  14. Pregnant or lactating female, or women trying to become pregnant.
  15. Known allergic reaction to components of study treatment and/or study injection procedure
  16. Subject has any disorder or any reason that may prevent compliance to study procedures and visits.
  17. Employees or family members of the study staff.
  18. Untreated or uncontrolled thyroid disorder (abnormal TSH/free T4) or diabetes mellitus (HgbA1C > 8.0).
  19. Subject who has a sensitive, irritated, or abraded scalp area.
  20. Clinically significant abnormal findings on laboratory screening panels:

    • Hemoglobin > or = 10 g/dL
    • Hepatic dysfunction, as defined as aspartate aminotransferase (AST), alanine aminotransferase (ALT), or bilirubin levels > 1.5 times the upper limit of normal range prior to randomization.
    • Chronic renal insufficiency as defined as a serum creatinine > 1.2 mg/dL for women and > 1.5 mg/dL for men.
    • Elevated PT/PTT, INR,
    • Platelet count < 100 x 109/L

Sites / Locations

  • Kenneth Williams, DORecruiting
  • Regeneris MedicalRecruiting
  • Regenevita LLCRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Active Comparator

Experimental

Experimental

Experimental

Arm Label

Control ARM 1

Emulsification tSVF + PRP ARM 2

Emulsification tSVF + PRP + cSVF ARM 3

cSVF in Normal Saline IV ARM 4

Arm Description

Control: 1) HD-PRP + Matristem Matrix (ACell) (Current Standard of Care); 2) Platelet Rich Plasma Concentrate)

HD-PRP + Emulsified AD-tSVF; Intervention: Platelet Rich Plasma Concentrate

tSVF; PRP; cSVF cell enriched biocellular therapeutic mix

cSVF + Normal Saline IV (500 cc) Infusion

Outcomes

Primary Outcome Measures

Safety of Intervention
Assess Adverse Events & Severe Adverse Events

Secondary Outcome Measures

Hair Growth Assessment
Trichogram Assessment Hair Growth
Photographic Assessment Scalp Hair
lobal Photographic Assessment of Scalp Hair
Investigator Satisfaction Survey
Treating Investigator Outcome Survey
Patient Satisfaction Outcome Survey
Patient Assessment of Outcome

Full Information

First Posted
March 6, 2017
Last Updated
April 15, 2020
Sponsor
Regeneris Medical
Collaborators
Global Alliance for Regenerative Medicine
search

1. Study Identification

Unique Protocol Identification Number
NCT03078686
Brief Title
Biocellular-Cellular Regenerative Treatment Scaring Alopecia and Alopecia Areata
Acronym
SAAA
Official Title
Biocellular Regenerative Therapy in Treating Scaring Alopecias and Alopecia Areata: Use of High Density Platelet-Rich Plasma Concentrates and Cell-Enriched Emulsified Adipose-Derived Tissue Stromal Vascular Fraction (AD-tSVF)
Study Type
Interventional

2. Study Status

Record Verification Date
April 2020
Overall Recruitment Status
Recruiting
Study Start Date
February 17, 2017 (Actual)
Primary Completion Date
January 22, 2025 (Anticipated)
Study Completion Date
June 22, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Regeneris Medical
Collaborators
Global Alliance for Regenerative Medicine

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The primary objective of this study is to evaluate the safety and efficacy of the use of a biocellular mixture of emulsified adipose-derived tissue stromal vascular fraction (AD-tSVF) and high density platelet-rich plasma concentrate (HD- PRP). Additionally, comparison with clinical outcomes of adipose-derived cellular Stromal Vascular Fraction (AD-cSVF) + AD-tSVF + HD PRP; AD-cSVF + emulsified AD-tSVF + HD- PRP; emulsified AD-tSVF + HD PRP + AD-cSVF; AD-cSVF via intravenous infusion in treatment of Scaring Alopecias and Alopecia Areata. Control will be served by use of established clinical protocol of using platelet concentrates with Matristem Matrix (Acel) injected in the same fashion as the other ARMs within this study, and comparative analyses performed at the endpoint of this study.
Detailed Description
The aesthetic surgical & cosmetic discipline of hair restoration is rooted in numerous landmark studies and progressive medical science in the medical literature. With the advent of advanced theories and science using cellular and platelet-derived growth factors within the scope of regenerative medicine, have been well established in a number of peer-reviewed publications, The use of biological modalities, e.g., HD-PRP concentrates (defined as > 4-6 times patient circulating baselines), have become recognized in a number of disciplines, including value of stimulation of scalp tissues and hair follicles in androgenetic alopecia (AGA). (See Clinical Trial Study STRAAND). A "retrograde" filling technique creating a potential space and subsequently injecting into this space will insure uniformity of placement and spread of the delivered treatment modality. This study design is intended to be a prospective, randomized, multi-center trial with blinding of outcomes for independent observers, clinical provider, and patient observation/satisfaction study comparatives. The study proposes adipose-derived cellular and stromal components when mixed with platelet high density concentrates (HD-PRP) offers an advantage to produce a markedly more effective therapeutic profile in in treating patients with scaring alopecia's (SA) and alopecia areata (AA), tissue age related senescence, and encourage vascular capabilities by stimulation of vasculoneogenesis. The benefits of using autologous adipose-derived stem & stromal cell (ADSC) populations are cell proliferation and vasculogenesis that is intrinsically linked with native inflammatory modulation and immunomodulatory capacities. Reports describing the safety and efficacy of this biocellular combination have been reported in peer reviewed literature. In the second and third arms of this study, use of regenerative protocols currently being extensively been utilized in the treatment of degenerative musculoskeletal conditions and plastic surgical procedures have been safely and effectively employed. These protocols feature the use of an emulsified AD-tSVF + HD PRP (ARM 2) compared to use of emulsified AD-tSVF + AD-cSVF (cell enrichment) + HD PRP (ARM 3) containing the full heterogeneous stem/stromal cell population and its native bioactive matrix. Addressing regions of scalp dermis containing the microenvironment (niche) of the hair follicle, progenitor tissues ("bulge"). In ARM 3, addition of cellular enrichment of the emulsified AD-tSVF is accomplished via a semi-automated, closed sterile system (Healeon CentriCyte 1000 system) which effectively isolates and concentrate the cellular elements. The AD-cSVF is then mixed with high-density platelet rich plasma (HD-PRP) concentrates with emulsified AD-tSVF tissues prior to targeted scalp injections. This injected cell-enriched product contains the bioactive native adipose tissue scaffolding, autologous HD-PRP, and cell-enriched adipose stem/stromal cellular concentrations of stromal/stem cells. In ARM 4 of this study, the addition of intravenous cellular deployment of isolated cSVF is performed following without direct injection to scalp sites. Observations in other trials have suggested that increased hair growth in shaft size, coloration and speed is noted in the majority of parenterally treated patients as an observed effect of infusions. In the future, clinical trial extension of this study will combine both the components shown in ARM 3 and add a concomitant ARM 4 to evaluate potential of stimulation of proliferative and regenerative potentials in the form of combined therapy. It has been noted by several investigators that parenteral us of AD-cSVF has had an unexpected outcome of improve hair growth and color change. All of the study ARMs (with exception of comparative control ARM 1) are tested by flow cytometry for viabilities and numbers, which will be statistically compared to outcomes following the study completion to examine whether a statistically significant difference in results follows with each ARM can be shown. The goal of this study is to demonstrate the safety and efficacy of each ARM. Biocellular injections into the scalp of men and women with a diagnosis of scaring alopecias and alopecia areata, with full reporting of AE and SAE (adverse events). In the intradermal injection portions of the study, the biocellular material is injected 3-5 mm in depth within the mid-reticular dermis to upper subcutaneous fat layer of the scalp. Placement of the biocellular and cell-enriched biocelluar is intended to examine changes associated with changes of the miniaturized hair follicle. It is hypothesized that delivery a milieu of stroma and stem/stromal cells will facilitate regenerative changes of the treatment sites. In addition to providing native bioactive tissue scaffolding, and a greater number of stromal/stem cells to the tissues surrounding the follicular niche will result in a positive effect. Use of small needles for delivery is made possible with incorporating the novel use of emulsification of adipose tissue complex (lipoaspirates) This emulsified AD-tSVF and HD PRP methodology reduces surgeon injection pressure requirements resulting with use of smaller gauge needles. When clinically compared to the use of much larger needles required to inject non-emulsified AD-tSVF, it is an improvement on current techniques. A "retrograde" filling technique creating a potential space and subsequently injecting into this space the biocellular material as the needle is withdrawn is advanced in this study. Successful stem/stromal cell-enrichment of AD-tSVF and HD PRP biocellular mixture has been reported in numerous peer-reviewed and published clinical experiences of injections for structural tissue augmentation in plastic surgery, chronic wound therapies, and ultrasound guided musculoskeletal treatments in orthopedic & sports medicine. Standard venipuncture for obtaining circulating whole blood is concentrating platelet components to create a low hematocrit HD-PRP using FDA approved E USA) Emcyte II following manufacturer's guidelines. Small volume closed syringe microcannula lipoaspiration is used to acquire AD-tSVF tissues(Tulip Medical GEMS, San Diego, CA,, followed by emulsification via the Healeon ACM System (Newbury Beach, CA, USA. Cellular testing of samples in Arm 2-4 will be performed by flow cytometry (ORFLO, MoxiFlow, Ketchum, ID, USA) for viability and cell concentrations. A detailed patient medical history, study informed consent, and screening evaluations will determine eligibility and candidacy for the study and complying with the inclusion/exclusion criteria. Recording of the platelet pre-operative measured baselines and achieved HD PRP concentrates, flow cytometric examination of cell viability, and cell counts of AD-cSVF should be completed on each patient. Biocellular injections and treatment will be given on two (2) separate procedures three (3) months apart. Follow up clinical examinations are to be performed at 6 months and 1 year period with completion of outcomes analyses including independent observer, clinician, and subject satisfaction. The volume of the therapueutic mix will be the standardized in volume for all trial ARMs. Immediate reporting to the study group for all AR and SAR will be documented and recorded for the safety records directly to Ken Williams, DO, as Co-Principal Investigator. This Clinical Trial will have a sample size of 60 patients at up to six (6) centers utilizing this protocol.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Alopecia Areata, Scarring Alopecia
Keywords
Stem Cells,PRP, tSVF,cSVF,Alopecia Areata,Scarring Alopecia

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Non-Randomized
Enrollment
60 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Control ARM 1
Arm Type
Active Comparator
Arm Description
Control: 1) HD-PRP + Matristem Matrix (ACell) (Current Standard of Care); 2) Platelet Rich Plasma Concentrate)
Arm Title
Emulsification tSVF + PRP ARM 2
Arm Type
Experimental
Arm Description
HD-PRP + Emulsified AD-tSVF; Intervention: Platelet Rich Plasma Concentrate
Arm Title
Emulsification tSVF + PRP + cSVF ARM 3
Arm Type
Experimental
Arm Description
tSVF; PRP; cSVF cell enriched biocellular therapeutic mix
Arm Title
cSVF in Normal Saline IV ARM 4
Arm Type
Experimental
Arm Description
cSVF + Normal Saline IV (500 cc) Infusion
Intervention Type
Procedure
Intervention Name(s)
tSVF by lipoaspiration
Intervention Description
Lipoaspiration Harvest tSVF closed syringe microcannula harvest, Tulip GEMS microcannula syringe system
Intervention Type
Procedure
Intervention Name(s)
PRP Concentration
Intervention Description
Preparation of High Density PRP Centrifugation per manufacturer directive, Emcyte II PurePRP System
Intervention Type
Procedure
Intervention Name(s)
Emulsification tSVF
Intervention Description
Preparation of emulsified tSVF harvested adipose; Use of ACM Device; Micronization of tSVF through Sterile Screen
Intervention Type
Procedure
Intervention Name(s)
cSVF isolation and concentration
Intervention Description
Healeon Centrifuge (CC1000) enzymatic digestion, incubation, isolation and neutralization to prepare cSVF concentrates
Intervention Type
Procedure
Intervention Name(s)
cSVF in Normal Saline IV
Intervention Description
cSVF + NS for IV Placement
Primary Outcome Measure Information:
Title
Safety of Intervention
Description
Assess Adverse Events & Severe Adverse Events
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Hair Growth Assessment
Description
Trichogram Assessment Hair Growth
Time Frame
12 months
Title
Photographic Assessment Scalp Hair
Description
lobal Photographic Assessment of Scalp Hair
Time Frame
12 months
Title
Investigator Satisfaction Survey
Description
Treating Investigator Outcome Survey
Time Frame
12 months
Title
Patient Satisfaction Outcome Survey
Description
Patient Assessment of Outcome
Time Frame
12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Males with a biopsy proven diagnosis of a Scaring alopecia (SA) or Alopecia Areata (AA) Females with a biopsy proven diagnosis of Scaring alopecia (SA) or Alopecia Areata (AA) Demonstrated ability to legally provide written informed consent and comply with the study requirements For women of childbearing potential with screening negative pregnancy test and subject agrees to avoid pregnancy with two forms of contraception for the duration of study Subject is willing to maintain existing and consistent hair length and color. Ability to complete study procedures, patient surveys, and photodocumentation. Subject is ≥ 18 years of age. Five (5) year cancer free period without treatment and no evidence of recurrence - Exclusion Criteria: Subjects who have used oral spironolactone, finasteride, dutasteride, minoxidil, or any oral or topical medication including over the counter and herbal medications for the treatment of hair loss within 12 months of study screening. Simultaneous treatment with an investigational product or procedure within 30 days, or planned future participation in another clinical study Subject has previously failed or has been deemed non-responsive to a previous experimental hair loss treatment. Subject must have no recent PRP, biocellular treatments, micro needling, cold laser therapies, or any other scalp or hair loss treatment. Subject with previously diagnosed or suspected unspecified dermatologic condition, or disorders that will make hair growth difficult (such as systemic burns, etc.). History of or active diagnosis of systemic autoimmune disease or organ transplantation or immunosuppressive medication(s). Receiving active cancer treatment or have present or previous malignancies except a history of squamous or basal skin cell carcinoma with excision for cure. Active systemic infection at the time of enrollment. If acquired afterwards, exclusion based on clinical judgment of investigator. Use of chronic antibiotics and/or systemic corticosteroids. Use of systemic agents that increase bleeding or clotting, or disorders associated with these effects, including patients receiving GIIB/IIIa inhibitors in the 2 weeks prior to the study procedure through to 1 week after the study procedure. Clinically significant or current medical or psychiatric illness. Prior surgery in the treatment area. Any disease or condition (medical or surgical) that, in the opinion of the investigator, might compromise dermatologic, hematologic, cardiovascular, pulmonary, renal, gastrointestinal, hepatic, or central nervous system function; or any condition that would place the subject at increased risk of increased morbidity or mortality. Pregnant or lactating female, or women trying to become pregnant. Known allergic reaction to components of study treatment and/or study injection procedure Subject has any disorder or any reason that may prevent compliance to study procedures and visits. Employees or family members of the study staff. Untreated or uncontrolled thyroid disorder (abnormal TSH/free T4) or diabetes mellitus (HgbA1C > 8.0). Subject who has a sensitive, irritated, or abraded scalp area. Clinically significant abnormal findings on laboratory screening panels: Hemoglobin > or = 10 g/dL Hepatic dysfunction, as defined as aspartate aminotransferase (AST), alanine aminotransferase (ALT), or bilirubin levels > 1.5 times the upper limit of normal range prior to randomization. Chronic renal insufficiency as defined as a serum creatinine > 1.2 mg/dL for women and > 1.5 mg/dL for men. Elevated PT/PTT, INR, Platelet count < 100 x 109/L
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Ryan Welter, MD, PhD
Phone
508.345.5492
Email
r.welter@regenerismedical.com
First Name & Middle Initial & Last Name or Official Title & Degree
Ken Williams, DO
Phone
1.949.333.2999
Email
drwilliams@iimsc.org
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Robert W Alexander, MD
Organizational Affiliation
GARM-USA
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Ken Williams, DO
Organizational Affiliation
IIMSC
Official's Role
Principal Investigator
Facility Information:
Facility Name
Kenneth Williams, DO
City
Irvine
State/Province
California
ZIP/Postal Code
92618
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ken Williams, DO
Phone
949-333-2999
Email
drwilliams@iimcs.org
First Name & Middle Initial & Last Name & Degree
Ryan Welter, MD, PhD
Facility Name
Regeneris Medical
City
North Attleboro
State/Province
Massachusetts
ZIP/Postal Code
02760
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ryan JP Welter, MD
Phone
508-345-5492
Email
r.welter@regenerismedical.com
First Name & Middle Initial & Last Name & Degree
Gabrielle Lewis
Phone
508.316.4268
Email
g.lewis@regenerismedical.com
First Name & Middle Initial & Last Name & Degree
Glenn C Terry, MD
First Name & Middle Initial & Last Name & Degree
Robert W Alexander, MD
First Name & Middle Initial & Last Name & Degree
Ryan JP Welter, MD,PhD
Facility Name
Regenevita LLC
City
Stevensville
State/Province
Montana
ZIP/Postal Code
59870
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Robert W Alexander, MD
Phone
406-777-5312
Email
rwamd@garm-usa.com
First Name & Middle Initial & Last Name & Degree
Susan Riley, CMA, Tech
Phone
+1.406.777.5312
Email
irbtrials@gmail.com
First Name & Middle Initial & Last Name & Degree
Glenn C Terry, MD
First Name & Middle Initial & Last Name & Degree
Robert W Alexander, MD
First Name & Middle Initial & Last Name & Degree
Ryan Welter, MD, PhD
First Name & Middle Initial & Last Name & Degree
Robert Niedbalski, DO
First Name & Middle Initial & Last Name & Degree
Lawrence Samuels, MD
First Name & Middle Initial & Last Name & Degree
Marco Barusco, MD
First Name & Middle Initial & Last Name & Degree
Ken Williams, DO

12. IPD Sharing Statement

Plan to Share IPD
Undecided
Citations:
PubMed Identifier
27788905
Citation
Alexander RW. Biocellular Regenerative Medicine: Use of Adipose-Derived Stem/Stromal Cells and It's Native Bioactive Matrix. Phys Med Rehabil Clin N Am. 2016 Nov;27(4):871-891. doi: 10.1016/j.pmr.2016.06.005.
Results Reference
background
PubMed Identifier
24236476
Citation
Li MD, Atkins H, Bubela T. The global landscape of stem cell clinical trials. Regen Med. 2014 Jan;9(1):27-39. doi: 10.2217/rme.13.80. Epub 2013 Nov 18.
Results Reference
background
PubMed Identifier
23357708
Citation
Hoareau L, Bencharif K, Girard AC, Gence L, Delarue P, Hulard O, Festy F, Roche R. Effect of centrifugation and washing on adipose graft viability: a new method to improve graft efficiency. J Plast Reconstr Aesthet Surg. 2013 May;66(5):712-9. doi: 10.1016/j.bjps.2012.12.033. Epub 2013 Jan 26.
Results Reference
background
PubMed Identifier
19679523
Citation
Conde-Green A, de Amorim NF, Pitanguy I. Influence of decantation, washing and centrifugation on adipocyte and mesenchymal stem cell content of aspirated adipose tissue: a comparative study. J Plast Reconstr Aesthet Surg. 2010 Aug;63(8):1375-81. doi: 10.1016/j.bjps.2009.07.018. Epub 2009 Aug 12.
Results Reference
background
PubMed Identifier
18317153
Citation
Kurita M, Matsumoto D, Shigeura T, Sato K, Gonda K, Harii K, Yoshimura K. Influences of centrifugation on cells and tissues in liposuction aspirates: optimized centrifugation for lipotransfer and cell isolation. Plast Reconstr Surg. 2008 Mar;121(3):1033-1041. doi: 10.1097/01.prs.0000299384.53131.87.
Results Reference
background
PubMed Identifier
20098110
Citation
Zhu M, Zhou Z, Chen Y, Schreiber R, Ransom JT, Fraser JK, Hedrick MH, Pinkernell K, Kuo HC. Supplementation of fat grafts with adipose-derived regenerative cells improves long-term graft retention. Ann Plast Surg. 2010 Feb;64(2):222-8. doi: 10.1097/SAP.0b013e31819ae05c.
Results Reference
background
PubMed Identifier
21393582
Citation
Koh YJ, Koh BI, Kim H, Joo HJ, Jin HK, Jeon J, Choi C, Lee DH, Chung JH, Cho CH, Park WS, Ryu JK, Suh JK, Koh GY. Stromal vascular fraction from adipose tissue forms profound vascular network through the dynamic reassembly of blood endothelial cells. Arterioscler Thromb Vasc Biol. 2011 May;31(5):1141-50. doi: 10.1161/ATVBAHA.110.218206. Epub 2011 Mar 10.
Results Reference
background
PubMed Identifier
23630430
Citation
Alexander RW, Harrell DB. Autologous fat grafting: use of closed syringe microcannula system for enhanced autologous structural grafting. Clin Cosmet Investig Dermatol. 2013 Apr 8;6:91-102. doi: 10.2147/CCID.S40575. Print 2013.
Results Reference
background
PubMed Identifier
26400925
Citation
Gentile P, Garcovich S, Bielli A, Scioli MG, Orlandi A, Cervelli V. The Effect of Platelet-Rich Plasma in Hair Regrowth: A Randomized Placebo-Controlled Trial. Stem Cells Transl Med. 2015 Nov;4(11):1317-23. doi: 10.5966/sctm.2015-0107. Epub 2015 Sep 23.
Results Reference
background
PubMed Identifier
23197782
Citation
Gentile P, Orlandi A, Scioli MG, Di Pasquali C, Bocchini I, Cervelli V. Concise review: adipose-derived stromal vascular fraction cells and platelet-rich plasma: basic and clinical implications for tissue engineering therapies in regenerative surgery. Stem Cells Transl Med. 2012 Mar;1(3):230-6. doi: 10.5966/sctm.2011-0054. Epub 2012 Feb 22.
Results Reference
background
Citation
Alexander, R.W., Understanding Adipose-Derived Stromal Vascular Fraction (AD-SVF) Cell Biology and Use on The Basis of Cellular, Chemical, and Paracrine Components. J of Prolo (2012), e855-869
Results Reference
background
PubMed Identifier
27553744
Citation
Elmaadawi IH, Mohamed BM, Ibrahim ZAS, Abdou SM, El Attar YA, Youssef A, Shamloula MM, Taha A, Metwally HG, El Afandy MM, Salem ML. Stem cell therapy as a novel therapeutic intervention for resistant cases of alopecia areata and androgenetic alopecia. J Dermatolog Treat. 2018 Aug;29(5):431-440. doi: 10.1080/09546634.2016.1227419. Epub 2018 Mar 6.
Results Reference
background
PubMed Identifier
27220016
Citation
Aronowitz JA, Lockhart RA, Hakakian CS, Birnbaum ZE. Adipose Stromal Vascular Fraction Isolation: A Head-to-Head Comparison of 4 Cell Separation Systems #2. Ann Plast Surg. 2016 Sep;77(3):354-62. doi: 10.1097/SAP.0000000000000831.
Results Reference
background

Learn more about this trial

Biocellular-Cellular Regenerative Treatment Scaring Alopecia and Alopecia Areata

We'll reach out to this number within 24 hrs